- Home
- OCUP vs FEAM Comparison
OCUP vs FEAM Comparison
Compare OCUP & FEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUP
- FEAM
- Stock Information
- Founded
- OCUP 2018
- FEAM 2016
- Country
- OCUP United States
- FEAM United States
- Employees
- OCUP N/A
- FEAM N/A
- Industry
- OCUP Biotechnology: Pharmaceutical Preparations
- FEAM Major Chemicals
- Sector
- OCUP Health Care
- FEAM Industrials
- Exchange
- OCUP Nasdaq
- FEAM Nasdaq
- Market Cap
- OCUP 53.1M
- FEAM 46.9M
- IPO Year
- OCUP N/A
- FEAM N/A
- Fundamental
- Price
- OCUP $1.32
- FEAM $0.69
- Analyst Decision
- OCUP Strong Buy
- FEAM Buy
- Analyst Count
- OCUP 3
- FEAM 4
- Target Price
- OCUP $18.67
- FEAM $4.19
- AVG Volume (30 Days)
- OCUP 86.6K
- FEAM 159.3K
- Earning Date
- OCUP 11-11-2024
- FEAM 11-07-2024
- Dividend Yield
- OCUP N/A
- FEAM N/A
- EPS Growth
- OCUP N/A
- FEAM N/A
- EPS
- OCUP N/A
- FEAM N/A
- Revenue
- OCUP $16,449,000.00
- FEAM N/A
- Revenue This Year
- OCUP N/A
- FEAM N/A
- Revenue Next Year
- OCUP $258.69
- FEAM $1,117.19
- P/E Ratio
- OCUP N/A
- FEAM N/A
- Revenue Growth
- OCUP N/A
- FEAM N/A
- 52 Week Low
- OCUP $1.15
- FEAM $0.40
- 52 Week High
- OCUP $3.53
- FEAM $3.35
- Technical
- Relative Strength Index (RSI)
- OCUP 48.70
- FEAM 58.83
- Support Level
- OCUP $1.25
- FEAM $0.45
- Resistance Level
- OCUP $1.35
- FEAM $0.50
- Average True Range (ATR)
- OCUP 0.08
- FEAM 0.08
- MACD
- OCUP 0.01
- FEAM 0.04
- Stochastic Oscillator
- OCUP 29.17
- FEAM 72.73
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
About FEAM 5E Advanced Materials Inc.
5E Advanced Materials Inc is engaged boron specialty advanced materials and lithium with a focus on enabling decarbonization, including electric transportation, clean energy, and food security.